Mihaylova Rositsa, Gevrenova Reneta, Petrova Alexandra, Savov Yonko, Zheleva-Dimitrova Dimitrina, Balabanova Vessela, Momekov Georgi, Simeonova Rumyana
Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia 1000, Bulgaria.
Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Sofia 1000, Bulgaria.
Plants (Basel). 2024 Jul 27;13(15):2086. doi: 10.3390/plants13152086.
The metabolic syndrome and its associated co-morbidities have been recognized as predisposing risk factors for the development of metabolic-associated fatty liver disease (MAFLD). The present study reports on the beneficial effect of the methanol-aqueous extract (ETB) at 150 and 300 mg/kg bw on biochemical parameters related to oxidative stress, metabolic syndrome, and liver function in rat animal models with induced MAFLD. ETB was found to be non-toxic with LD50 > 3000 mg/kg and did not affect cell viability of hepatic HEP-G2 cells in a concentration up to 800 μg/mL. The pathology was established by a high-calorie diet and streptozotocin. Acarbose and atorvastatin were used as positive controls. At the higher dose, ETB reduced significantly ( < 0.05) the blood glucose levels by about 20%, decreased lipase activity by 52%, total cholesterol and triglycerides by 50% and 57%, respectively, and restored the amylase activity and leukocytes compared to the MAFLD group. ETB ameliorated oxidative stress biomarkers reduced glutathione and malondialdehyde in a dose-dependent manner. At 300 mg/kg, the beneficial effect of the extract on antioxidant enzymes was evidenced by the elevated catalase, glutathione peroxidase, and superoxide dismutase activity by 70%, 29%, and 44%, accordingly, compared to the MAFLD rats. ETB prevents the histopathological changes related to MAFLD. ETB, rich in 3,5-dicafeoylquinic, chlorogenic, and rosmarinic acids together with the isorhamnetin- and luteolin-glucoside provides a prominent amelioration of MAFLD.
代谢综合征及其相关合并症已被公认为是代谢相关脂肪性肝病（MAFLD）发生发展的易感风险因素。本研究报告了甲醇 - 水提取物（ETB）在150和300 mg/kg体重剂量下，对诱导性MAFLD大鼠动物模型中与氧化应激、代谢综合征和肝功能相关的生化参数的有益作用。发现ETB无毒，半数致死量> 3000 mg/kg，在浓度高达800 μg/mL时不影响肝源性HEP-G2细胞的细胞活力。通过高热量饮食和链脲佐菌素建立病理模型。阿卡波糖和阿托伐他汀用作阳性对照。与MAFLD组相比，在较高剂量下，ETB显著降低（<0.05）血糖水平约20%，降低脂肪酶活性52%，总胆固醇和甘油三酯分别降低50%和57%，并恢复淀粉酶活性和白细胞水平。ETB以剂量依赖的方式改善氧化应激生物标志物还原型谷胱甘肽和丙二醛。与MAFLD大鼠相比，在300 mg/kg剂量下，提取物对抗氧化酶的有益作用表现为过氧化氢酶、谷胱甘肽过氧化物酶和超氧化物歧化酶活性分别升高70%、29%和44%。ETB可预防与MAFLD相关的组织病理学变化。富含3,5 - 二咖啡酰奎宁酸、绿原酸和迷迭香酸以及异鼠李素和木犀草素糖苷的ETB可显著改善MAFLD。
